Allergios® – We see allergy.

Did you know?

Allergy is among the world’s most common chronic diseases
20% of the world population suffers from an allergy
Current test methods (particularly for food allergy) are not sufficient for an unambiguous allergy diagnosis

Allergios’^® direct allergy test enables patients to be better diagnosed and effectively treated

The Challenge

Allergy is among the most common chronic diseases worldwide. Up to 20% of patients with allergies live with a severe debilitating form of their condition, and struggle daily with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction (EAACI, 2016).

Our Solution

Researchers from the University of Bremen, supported by colleagues at the Medical University of Vienna, have developed a method and system that can directly diagnose allergies by visualizing the allergic response:

the ability of immunological factors in patient blood to induce degranulation of basophils in the presence of allergen

Allergios^® offers an effective and scalable In – vitro allergy diagnostic, which works by visually analyzing how a few drops of blood serum enable allergen-specific degranulation of basophil cells. Armed with a disposable microfluidic chip, an optical reader (GranulEye^®) and AI based analysis software, allergy tests can be run safely and easily, enabling clinicians to provide timely effective treatment options based on a clear and unambiguous diagnosis by the Allergios^® allergy test.

Allergios will initially focus on Food Allergies (replacing the Food Challenge test and the skin prick test) and then gradually expand to Inhalent and other IgE-mediated allergies.

Allergios^®– We see allergy.

We see allergy

Our Core Team

Prof. Michael Vellekoop

Inventor

Co-Founder

Dr. Sander van den Driesche

Inventor

Co-Founder

Folkert Roossien

Chief Development Officer

Co-Founder

Ernst Elhorst

Chief Executive Officer

Co-Founder

Advisory Board

Prof. Dr. Heimo Breiteneder

World-renowned expert on the molecular biology of allergens

Inventor

Dr. Christine Hafner

Clinical allergist and dermatologist with a focus on molecular allergy diagnostics

Inventor

Dr. Claas Falldorf

BIAS Germany

Inventor

Gina Melchner

NLC

Venture Partner

Company update

Allergios^® has successfully completed the Biological Validation of the Allergios® allergy test in a clinical setting (reaching TRL 5), immensely de-risking the innovation.

Having completed the Biological Validation, Allergios^® will focus on raising new capital, aiming for Series-A funding of €2.5m (of which 40% is secured).

Proceeds of this new financing round will be used to optimize the GranulEye and do further clinical testing, preparing ourselves for clinical trials under IVDR and FDA guidelines

We have secured our basic innovation by filing for US and EUR patents, we are currently expanding IP coverage (with flanking IP’s). Both patents have been issued the remarks by the patent offices: “IP to be granted.”

News

Allergios is awarded HealthHolland grant funding, recognition of the relevance of our innovative IVD test for food allergies

10 October 2024

Allergios is proud to announce a public-private-partnership with Wageningen University & Research, supported by Health-Holland, Top Sector Life Sciences & Health. The objective of this partnership is to validate an innovative test for the diagnosis of food allergy, the GranulEye test.

Dr. ir. Janneke Ruinemans-Koerts (clinical chemist at Rijnstate Hospital/Dicoon laboratories and associate professor at Wageningen University & Research) will lead the analytical and clinical validation of the GranulEye for the diagnosis of peanut allergy. This in vitro diagnostic system measures the basophil activation by visualization of stimulated basophils by e.g. peanut allergen. This novel method of basophil activation measurement will be compared with the current methods of basophil activity analysis (Basophil Activation Test).

Current tests to diagnose allergy such as the skin prick test and the IgE blood tests, indicate sensitization to allergens, but not necessarily an allergic clinical response. The current gold standard, the double-blind placebo-controlled food challenge can induce severe allergic reactions, is burdensome for the patient, is time-consuming and costly. Allergios’ in vitro diagnostic test offers the promise of a clear, accurate test without these drawbacks.

Folkert Roossien, Co-Founder and Chief Development Officer at Allergios, is gratified not only by the scientific collaboration with Wageningen University & Research but also by the support from Health-Holland. “We’ve always been excited by the science of our innovation, but ultimately we’re most excited by the interest of the clinicians and the impact it will bring to allergy sufferers. This partnership will bring us one step closer to having that impact. A more reliable test to diagnose an actual food allergy can be considered as a breakthrough.”

Contact us

"*" indicates required fields

info@allergios.health